Newsroom | 5161 results

LONDON & ROME--(BUSINESS WIRE)--Keyron today announced publication in Gut, the highest-ranked gastroenterology journal globally (Impact Factor: 26.2), demonstrating that its ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomized preclinical study. Widely regarded as the most metabolically effective and invasive bariatric...

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten...

NEW YORK--(BUSINESS WIRE)--HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis usin...

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D...

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada....

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. “We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom’s president and CEO. “Today’s a...

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp...

MADISON, Wis.--(BUSINESS WIRE)--Navitus today released its 10th annual Drug Trend Report, “Clarity for Action,” the company’s flagship annual analysis of prescription drug cost trends. The report details how utilization growth and therapeutic innovation drove prescription drug costs in 2025 and outlines clear actions for health plans and plan sponsors to counter accelerating pressure. Across the Navitus commercial book of business, net prescription drug costs increased 8.4%, up from 7% in 2024,...

GOTHENBURG, Svezia e BURGDORF, Svizzera--(BUSINESS WIRE)--Glooko, Inc. e mylife Diabetes Care oggi hanno reso noto un accordo per ampliare ulteriormente la loro collaborazione, che prevede che Glooko serva da piattaforma primaria per la gestione dei dati di mylife Diabetes Care per i prodotti mylife. Questa nuova iniziativa si basa sulla stretta collaborazione ben consolidata tra le due aziende, garantendo la continuità delle modalità di accesso ai dati da parte dei pazienti e dei professionist...

GÖTEBORG, Zweden & BURGDORF, Zwitserland--(BUSINESS WIRE)--Glooko, Inc. en mylife Diabetes Care hebben vandaag een overeenkomst aangekondigd om hun samenwerking verder uit te breiden. Glooko zal fungeren als het primaire databeheerplatform van mylife Diabetes Care voor mylife-producten. Deze volgende stap bouwt voort op het sterke, reeds lang bestaande samenwerkingsverband tussen de twee bedrijven en zorgt voor continuïteit in de manier waarop zorgprofessionals en patiënten toegang krijgen tot...